https://www.globenewswire.com/news-release/2022/08/29/2505681/0/en/Checkpoint-Inhibitors-for-Treating-Cancer-Market-Worth-US-63-420-2-Million-by-2031-Visiongain-Reports-Ltd.html
So far Zantrene as A FTO inhibitor has FIC and BIC status. Imagine if RAC can prove Zantrene has synergies and helps these Checkpoint Inhibitors to overcome drug resistance in HUMAN, the commercial value is mind-blowing.Not long to go we will know.AIMO
Note:
We have a very good chance see link
https://www.sciencedirect.com/science/article/abs/pii/S2405803322000541
Industry news, page-790
-
- There are more pages in this discussion • 1,065 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.55 |
Change
-0.070(4.32%) |
Mkt cap ! $264.0M | |||
| Open | High | Low | Value | Volume |
| $1.62 | $1.65 | $1.54 | $145.6K | 91.60K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5700 | $1.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 296 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |